- Company
- Whether Gardasil 9's supply price increase is reasonable
- by Jun 14, 2022 06:04am
- In order to improve the accessibility of vaccines monopolized by foreign companies, it was suggested that reasonable pricing should be monitored and institutional support measures for self-reliance should be actively reviewed. The Korea Biotechnology Industry Organization Bioeconomic Research Center said in a report titled "Controversy ove
- Company
- Hanall Biopharma to expand HL161 development in earnest
- by Chon, Seung-Hyun Jun 10, 2022 05:44am
- Hanall Biopharma announced on the 9th that its U.S. partner Imunovant will expand the development of HL161 (code name IMVT-1401), which is being developed as a SC autoimmune treatment. Phase 3 clinical trials for severe work history will begin this month and the results of the top line in 2024 will be confirmed. According to Immunovant, there
- Company
- Exports of CKD·Dong-A ST's antianemic biosimilars increase
- by Chon, Seung-Hyun Jun 10, 2022 05:43am
- The biosimilar products developed by Chong Kun Dang and Dong-A ST are starting to make their way into the overseas market, with its Nesp biosimilars starting to generate sales in earnest abroad. Although the companies’ products did not show explosive growth upon entry, the products are increasing their presence in the market. According to th
- Company
- Sanofi & 4 other companies will participate in NIP
- by Lee, Tak-Sun Jun 10, 2022 05:42am
- Unlike the previous year, Sanofi Pasteur is expected to participate as a new business operator and Ilyang Pharmaceutical is expected to be excluded. As a result of the bidding conducted through the Nara Market of the Public Procurement Service on the 9th, Sanofi Pasteur was selected as the first choice by writing the lowest price of 14,433
- Company
- Hanmi’s new biologic receives orphan designation in Europe
- by Chon, Seung-Hyun Jun 10, 2022 05:42am
- New drug products being developed by Hanmi Pharmaceutical have received a total of 20 orphan drug designations from regulatory authorities in Korea and abroad. Hanmi Pharmaceutical announced on the 9th that the European Medicines Agency granted an orphan drug designation for its new triple action biologic drug LAPS Triple Agonist (HM15211)
- Company
- Jeil and Amgen agree to co-sell PCSK9 inhibitor Repatha
- by Nho, Byung Chul Jun 10, 2022 05:42am
- Jeil Pharmaceutical (CEO Seong Seok-je) and Amgen Korea (CEO Noh Sang-kyung) announced on the 7th that they signed a joint sales contract for Repatha for patients with atherosclerosis cardiovascular disease and hypercholesterolemia as of the 1st of this month. With this joint sales contract, Jeil Pharmaceutical and Amgen Korea will conduct
- Company
- Genomictree's colorectal cancer business is booming
- by Lee, Seok-Jun Jun 9, 2022 06:23am
- FS Research highly evaluated Genomictree's growth potential in a report on the 8th. Genomictree is a company that discovers biomarkers, verifies clinical efficacy, and develops and sells early diagnosis products for various cancers (colonial cancer, lung cancer, bladder cancer, etc.). According to the report, sales of Genomictree's colorec
- Company
- Impurity data on schizophrenia and asthma drugs submitted
- by Chon, Seung-Hyun Jun 8, 2022 05:56am
- Pharmaceutical companies are submitting results of their impurity inspections on the schizophrenia treatment ‘Quetiapine’ and asthma and allergic rhinitis treatment ‘Montelukast’ one after another. As of now, no product has been recalled due to excessive impurities, and the health authorities plan to take follow-up measures after reviewi
- Company
- Avodart leads 6th quarter
- by Kim, Jin-Gu Jun 8, 2022 05:56am
- Dutasteride are strong in the domestic hair loss treatment market. Both original and generic recorded higher sales growth than competitive drug Finasteride. According to IQVIA, a pharmaceutical market research firm, on the 2nd, GSK Avodart's sales in the first quarter were 10.7 billion won, up 9% from 9.9 billion won in the first quarter of l
- Company
- Sales of Nexavar fell sharply
- by Jun 8, 2022 05:55am
- Sales of Nexavar, which has dominated the primary treatment market for liver cancer for 10 years, are falling. This is because prices have fallen due to the release of generic products, and the status of the first treatment for liver cancer as a new drug has been shaken. Compared to two years ago, quarterly sales have halved. ◆Tecentriq w
